| Literature DB >> 32331925 |
Rui Chang1, Lin Chen1, Guannan Su1, Liping Du2, Yang Qin1, Jing Xu1, Handan Tan1, Chunjiang Zhou1, Qingfeng Cao1, Gangxiang Yuan1, Aize Kijlstra3, Peizeng Yang4.
Abstract
Combination of corticosteroids (CS) with cyclosporin A (CsA) is widely used in the treatment of autoimmune diseases, autoinflammatory diseases and transplantation rejection. However, some patients fail to respond or develop resistance to the combination regimen. In Vogt-Koyanagi-Harada (VKH) disease model, we performed RNA sequencing (RNA-seq) based transcriptomics, isobaric tags for relative and absolute quantification (iTRAQ) based proteomics and assays in vitro to screen and validate potential resistant molecules. We found that a total of 1697 differentially expressed genes (DEGs) and 21 differentially expressed proteins (DEPs) in CD4+ T cells between CsA & CS-resistant and -sensitive VKH patients. Ribosomal Protein S4, Y-Linked 1 (RPS4Y1) was verified to regulate the resistance of CD4+ T cells from male VKH patients to CsA & CS. Importantly, we showed that chlorambucil (CLB) could reverse the resistance by RPS4Y1 suppression. Taken together, we identify RPS4Y1 as an important CsA & CS resistance gene in VKH disease. Researchers should consider validating the resistant effect of RPS4Y1 in other autoimmune diseases or organ transplantation.Entities:
Keywords: CLB; CsA & CS resistance; Proteomics; RPS4Y1; Transcriptomics; VKH disease
Mesh:
Substances:
Year: 2020 PMID: 32331925 DOI: 10.1016/j.jaut.2020.102465
Source DB: PubMed Journal: J Autoimmun ISSN: 0896-8411 Impact factor: 7.094